NEW YORK, April 8, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Encana Corporation (NYSE: ECA), Perrigo Company PLC (NYSE: PRGO),
The Boeing Company (NYSE: BA), Genworth Financial Inc. (NYSE: GNW),
and Itau Unibanco Holding SA (NYSE: ITUB). Private wealth members
receive these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Encana Corporation Analyst Notes
On March 31, 2014, Encana
Corporation (Encana) disclosed that its wholly-owned subsidiary,
Encana Oil & Gas (USA) Inc.,
has arrived at an agreement with an affiliate of TPG Capital (TPG)
to sell certain natural gas properties in the Jonah field located
in Sublette County, Wyoming, for a
purchase price of about $1.8 billion.
According to the Company, the transaction also includes over
100,000 undeveloped acres adjacent to Jonah known as the Normally
Pressured Lance area. As stated, Encana's Jonah assets sale is
expected to close in Q2 2014 with an effective date of December 1, 2013. Commenting on the development,
Doug Suttles, Encana President &
CEO said, "This transaction is consistent with our strategy. With
the divestment of Jonah, we are unlocking value from a mature,
high-quality asset and allowing our teams to focus on our five core
growth areas and continue with execution of our new strategy." The
full analyst notes on Encana Corporation are available to download
free of charge at:
http://www.AnalystsReview.com/04082014/ECA/report.pdf
--
Perrigo Company PLC Analyst Notes
On April 1, 2014, Perrigo Company
(Perrigo) introduced a new product under its umbrella and made its
first shipments of the authorized generic version of LEO Pharma
A/S' Taclonex® Ointment (calcipotriene 0.005% / betamethasone
dipropionate 0.064%). Taclonex® Ointment is suggested for the
treatment of plaque psoriasis of the scalp and body in patients, of
18 years and above. As stated, the brand sales amounted to nearly
$110 million over the last 52 weeks.
In relation with the Company's latest product launch, Joseph C. Papa, Chairman, President and CEO
said, "This product was the result of the continued hard work and
dedication of our Perrigo Rx team. This launch is another example
of Perrigo's investment and commitment to making quality healthcare
more affordable for consumers." The full analyst notes on Perrigo
Company PLC are available to download free of charge at:
http://www.AnalystsReview.com/04082014/PRGO/report.pdf
--
The Boeing Company Analyst Notes
On April 3, 2014, Boeing Company
(Boeing) reported its deliveries across the commercial and defense
operations for Q1 2014 (period ended March
31, 2014). As reported by the Company, a total of 161
deliveries were made under the commercial airplanes programs, of
which 737 Next Generation airplanes accounted for 115 deliveries in
the quarter. According to the Company, 24 deliveries of 777 were
made, making it the second highest delivered airplane, whereas no
deliveries were reported for 767 during the same time period.
According to the release, under the Defense, Space and Security
Programs, 17 Chinook (New Builds) and 11 F/A-18E/F and EA-18G were
delivered. The full analyst notes on The Boeing Company are
available to download free of charge at:
http://www.AnalystsReview.com/04082014/BA/report.pdf
--
Genworth Financial Inc. Analyst Notes
On March 25, 2014, Genworth
Financial Inc. (Genworth) issued a press release disseminating the
reading for the Genworth Homebuyer Confidence Index, which declined
to 90.8 points in March 2014 from
92.4 points in September 2013. The
Company attributed the decline to a fall in confidence in the first
homebuyer segment and cost of living pressures for mortgage
holders. According to Genworth, the first homebuyers' component has
fallen from 85.0 in September 2013 to
82.3 in March 2014, mainly led by
concerns around underemployment. Confirming the decline in the
Homebuyer Confidence Index, Bridget
Sakr, Chief Commercial Officer of Genworth Australia said,
"The marginal decline in confidence was driven largely by
homebuyers experiencing or expecting mortgage stress." In addition,
the proportion of those surveyed that thought that now was a good
time to buy a home weakened from 46% in September 2013 to 42% in March 2014. The full analyst notes on Genworth
Financial Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04082014/GNW/report.pdf
--
Itau Unibanco Holding SA Analyst Notes
On April 3, 2014, shares in Itau
Unibanco Holding S.A. (Itau Unibanco) fell 1.88% to end the trading
session at $15.17. The stock opened
the session at $15.38, and traded in
the range of $15.04 - $15.38, with a
total of 14.10 million shares changing hands during the day. On
April 1, 2014, a news article on
Reuters reported that the U.S. investment firm Cartica
Management LLC ("Cartica") has filed a lawsuit in New York against Chilean bank CorpBanca SA,
its controlling shareholder, Álvaro Saieh, and his investment
holding company over a plan to merge with Brazil's Itaú Unibanco Holding Financeira SA.
The merger was announced on January 29,
2014, and the share price of Itau Unibancoahs has increased
26.95% since then. As per the news article, Cartica has alleged
that the deal with Itau Unibanco, undervalues CorpBanca's shares,
so as to give special benefits to Saieh, a Chilean billionaire, and
his company CorpGroup. The full analyst notes on Itau Unibanco
Holding SA are available to download free of charge at:
http://www.AnalystsReview.com/04082014/ITUB/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Ananya
Ghosh, a CFA charterholder. However, we are only human and
are prone to make mistakes. If you notice any errors or omissions,
please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Ananya Ghosh, CFA,
has only reviewed the information provided by Analysts Review in
this article or report according to the Procedures outlined by
Analysts Review. Analysts Review is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review